HalioDx SAS, an immuno-oncology diagnostic company, today announced that Pronto Diagnostics will market and distribute Immunoscore® Colon assay in Israel.
Oncologists and patients in Israel will have access to Immunoscore® Colon, a unique diagnostic assay that predicts the risk of recurrence of patients with early stage colon cancer. The assay guides oncologists to decide on critical therapeutic options in stage II and stage III colon cancers. Immunoscore® Colon combines tissue diagnostic and advanced image analysis technologies to quantify T-cells which infiltrate both the core of the colon tumor and its invasive margin. It is the very first IVD assay of the HalioDx Immunoscore® pipeline, leveraging image analysis technology to enhance clinical utility and standardization.
Immunoscore® Colon will be marketed in Israel by CTS Ltd, one of the leading Israeli pharma companies, through a joint cooperation between Pronto Diagnostics and CTS.
“Colorectal cancer is the second most common malignant disease in Israel. According to the Israeli Ministry of Health most recent data in 2015 there were 3,016 new cases of Colorectal cancer of which ~ 2,228 are Colon cancer. We estimate that for approximately half of these cases the access to Immunoscore® Colon will enable physicians to assess better Colon cancer recurrence risk and adjust therapeutic options accordingly. We are excited to add Immunoscore® Colon to our portfolio of testing services in Israel and proud to introduce this important test to the Israeli market”, noted Nir Navot, CEO of Pronto Diagnostics.
“We are delighted to collaborate with Pronto Diagnostics, an expert company enabling Israeli oncologists and patients to access value-based diagnostic solutions,” added Vincent Fert CEO of HalioDx.
Immunoscore® Colon was discovered by Dr. Jérôme Galon and developed in compliance with the IVD standards by HalioDx. The clinical value has been validated in several studies on early stage colon cancer patients. Recently the results of the SITC International study conducted on more than 2600 patients have been published in The Lancet journal. The prognostic value has also been validated on 600 stage III colon cancer patients from the FOLFOX arm of the prospective NCCTG N0147 study.